Biocartis Earns European Certification for Colorectal Cancer Companion Diagnostic Test
The Idylla CDx MSI Test detects microsatellite instability in colorectal cancer tissue in under three hours, supporting therapy selection for eligible patients.
Category: Molecular Diagnostics
Molecular Diagnostics
Latest
Molecular Diagnostics
Latest
CSF Liquid Biopsy Delivers 82% Clinical Impact Rate in CNS Lymphoma Cases
A retrospective study in Lymphatics reports that CSF liquid biopsy testing delivered clinical impact in 82% of CNS lymphoma cases, resolving diagnoses and informing treatment when standard methods were inconclusive.
Molecular Diagnostics
Latest
MyOme Adds Methylation Analysis to Whole-Genome Platform and Partners with Natera on New Test Portfolio
The Menlo Park-based company is integrating epigenetic signatures into its rare disease diagnostics offering, with the new capability set to roll out automatically in early Q2 2026.
New ctDNA Assay Aims to Detect Molecular Residual Disease Earlier in Solid Tumors
Tumor-informed blood test uses whole-exome sequencing and bioinformatics to identify trace tumor DNA before recurrence appears on imaging.
Read More
Three-Year NHS Study Shows Blood Test Reduces Stage IV Cancer Diagnoses
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
Read More
Syndex Bio Unveils DNA Methylation Technology After $15.5M Funding Round
The mcPCR platform enables copying of DNA methylation patterns during amplification, addressing a key limitation in current PCR methods for disease detection.
Read More
Ultima Genomics Introduces UG200 Series Sequencing Systems with Doubled Output
The new platform delivers twice the throughput in half the footprint of the previous generation, targeting large-scale genomic applications.
Read More
Why Spatial Omics Is Transitioning From ‘Maps’ to ‘Mechanisms’
High-resolution maps showed us where cells live; the next phase of spatial omics is about extracting those cells and uncovering the molecular conversations that shape outcomes.
Read More
Thermo Fisher Introduces Sequential Protein/DNA/RNA Extraction Kit
Thermo Fisher Scientific has launched a kit enabling sequential extraction of protein, DNA, and RNA from a single sample, supporting multi-omics cancer research and downstream mass spectrometry and sequencing applications.
Read More
Singular Genomics Launches High-Throughput Spatial Analysis Platform in US
The G4X system can analyze 128 samples per run with 500-plex RNA and 18-plex protein capabilities, targeting translational research and clinical applications.
Read More
Cirena Launches Long RNA Synthesis Platform for CRISPR Applications
The technology is designed to deliver high-purity long RNA to support CRISPR and functional genomics workflows.
Read More
BillionToOne Launches Two Liquid Biopsy Add-On Tests for Cancer Therapy Selection
BillionToOne has launched Northstar PGx and Northstar Select CH, two liquid biopsy add-on tests for advanced solid tumor therapy selection, enabling pharmacogenomic insights and clonal hematopoiesis detection from a single blood draw.
Read More
New Test Strip Detects Cancer Biomarkers at Ultra-Low Concentrations
Researchers at La Trobe University have developed a single-use test strip that detects cancer-related microRNAs in blood plasma at concentrations up to 1,000 times lower than current methods.
Read More
Ambry Genetics Reaches 1 Million RNA-Enhanced Genetic Tests
Ambry Genetics has completed its one millionth DNA/RNA genetic test, highlighting increased adoption of RNA-enhanced diagnostics for hereditary cancer and rare diseases, according to the company.
Read More
Bipartisan Bill Would Expand Medicaid Coverage for Pediatric Genomic Sequencing
A bipartisan House bill would require Medicaid to cover whole genome and exome sequencing for children with suspected rare diseases, aiming to improve diagnostic access and reduce costs, according to lawmakers and recent pilot programs.
Read More
New Standards Issued for Liquid Biopsy Cancer Recurrence Tests
The BLOODPAC Consortium has released new analytical validation standards for liquid biopsy MRD tests, offering industry-wide protocols for tumor-informed ctDNA assay development, as detailed in JCO Precision Oncology.
Read More
New Method Shows Superior Sensitivity in Liquid Biopsy Testing
Bridge Capture, a targeted NGS method, showed higher sensitivity for detecting rare ctDNA variants than two leading liquid biopsy assays, according to research in The Journal of Molecular Diagnostics.
Read More
Whole-Genome Sequencing Algorithm Shows Promise for PARP Inhibitor Selection
Weill Cornell Medicine researchers report a whole-genome sequencing algorithm may identify more patients for PARP inhibitor cancer therapies than current commercial tests, according to a study in Communications Medicine.
Read More